Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

  • Abbott Laboratories ABT has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50.
  • Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion.
  • Worldwide sales, excluding COVID-19 testing-related sales, increased 3.9% on a reported basis and 7.7% on an organic basis.
  • Related: Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings.
  • Global COVID-19 testing-related sales were $3.3 billion, led by sales of rapid testing products.
  • Medical Devices sales increased 7.4% to $3.56 billion on a reported basis and 11.5% organically, driven by double-digit organic growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.
  • Outlook: Abbott's FY22 adjusted EPS outlook of at least $4.70 remains unchanged (consensus $4.83).
  • 2022 guidance includes projected COVID-19 testing-related sales of approximately $4.5 billion, which Abbott expects to primarily occur in 1H of 2022 and will update quarterly.
  • Price Action: ABT shares are down 2.07% at $117.50 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!